Parallel Advisors’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$54.4K Hold
2,561
﹤0.01% 1950
2025
Q4
$41.8K Buy
2,561
+55
+2% +$831 ﹤0.01% 1927
2025
Q3
$29.3K Hold
2,506
﹤0.01% 2068
2025
Q2
$29K Sell
2,506
-15,082
-86% -$137K ﹤0.01% 2014
2025
Q1
$154K Buy
17,588
+2,686
+18% +$33.9K ﹤0.01% 1071
2024
Q4
$214K Sell
14,902
-2,321
-13% -$36.6K ﹤0.01% 905
2024
Q3
$389K Buy
17,223
+1,118
+7% +$23.1K 0.01% 664
2024
Q2
$313K Sell
16,105
-489
-3% -$12.8K 0.01% 702
2024
Q1
$623K Sell
16,594
-7
-0% -$308 0.02% 468
2023
Q4
$929K Sell
16,601
-773
-4% -$33.6K 0.03% 350
2023
Q3
$717K Buy
17,374
+4
+0% +$208 0.02% 374
2023
Q2
$970K Sell
17,370
-9
-0.1% -$487 0.03% 318
2023
Q1
$970K Sell
17,379
-3,010
-15% -$141K 0.03% 316
2022
Q4
$743K Buy
20,389
+154
+0.8% +$5.04K 0.03% 314
2022
Q3
$576K Buy
20,235
+69
+0.3% +$2.63K 0.03% 358
2022
Q2
$913K Sell
20,166
-68
-0.3% -$3.53K 0.04% 259
2022
Q1
$1.51M Buy
20,234
+12,810
+173% +$1.12M 0.06% 206
2021
Q4
$1.11M Buy
7,424
+7,414
+74,140% +$1.14M 0.04% 255
2021
Q3
$1K Sell
10
-1
-9% -$172 ﹤0.01% 2969
2021
Q2
$2K Sell
11
-3,469
-100% -$628K ﹤0.01% 2624
2021
Q1
$630K Buy
3,480
+3,462
+19,233% +$598K 0.03% 310
2020
Q4
$3K Buy
+18
New +$2.61K ﹤0.01% 2227

Other funds holding TXG

Parallel Advisors's TXG Position: Q1 2026 in Review

Parallel Advisors held its 10x Genomics (TXG) position steady in Q1 2026 at 2,561 shares worth $54.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1950.

Parallel Advisors first reported a position in TXG in Q4 2020 and has held it in 22 quarters since. The position peaked at $1.51M in Q1 2022. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Parallel Advisors held 2,561 shares of 10x Genomics worth $54.4K as of Q1 2026.
  • Parallel Advisors left its 10x Genomics share count unchanged in Q1 2026.
  • 10x Genomics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1950 holding.
  • Parallel Advisors first reported a position in 10x Genomics in Q4 2020 and has held it in 22 quarters since.
  • Parallel Advisors's 10x Genomics position peaked at $1.51M in Q1 2022.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.